Search Results
Your search for ,ITS matches 8694 pages
Showing 8601 - 8650FDA Grants Orphan Drug Status to Eisai’s Investigational Compound E7777 for Cutaneous T-Cell Lymphoma
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Eisai’s investigational compound E7777 for cutaneous T-cell lymphoma. E7777 is designed to have an improved purity profile and manufacturing process. It is currently in a pivotal trial intended to support ...
Vaccine Stirs Immune Activity Against Advanced Chronic Lymphocytic Leukemia
Patients with advanced chronic lymphocytic leukemia (CLL) often receive allogeneic transplants that effectively “reboot” their own immune defenses, which then attack and potentially cure the hard-to-treat disease. However, there is a high rate of relapse in these patients, and the...
Study Reveals Genes That Drive Glioblastoma
A team of researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center has identified 18 new genes responsible for driving glioblastoma multiforme, the most common—and most aggressive—form of brain cancer in adults. The study was published online...
Researchers Target ‘Cell Sleep’ to Lower Chances of Cancer Recurrence
An international research team led by scientists at the University of Pittsburgh Cancer Institute (UPCI) discovered that by preventing cancer cells from entering a state of cellular sleep, cancer drugs are more effective, and there is a lower chance of cancer recurrence. The findings, published...
Targeted Therapy Identified for Protein that Protects and Nourishes Cancer
Scientists at The University of Texas MD Anderson Cancer Center who identified a protein’s dual role in cancer promotion have discovered a way to shut it down, opening a potential new avenue for cancer treatment. Reporting their findings in the journal Cell, the researchers describe the first ...
Blocking Sugar Intake May Reduce Cancer Risk or Progression in Certain Malignant Tumors
Blocking dietary sugar and its activity in tumor cells may reduce cancer risk and progression, according to researchers from the Icahn School of Medicine at Mount Sinai in New York. The study, conducted in fruit flies and published in the August issue of Cell, provides insight as to why...
James L. Mulshine, MD, Comments on U.S. Preventive Services Task Force Recommendations for CT Screening for Lung Cancer in High-risk Individuals
The recommendation by the U.S. Preventive Services Task Force (USPSTF) for the use of low-dose, computed tomography (CT) to detect early lung cancer in high-risk individuals is a major milestone in the war on cancer. Lung cancer is the leading cause of cancer death across the world. Despite...
U.S. Preventive Services Task Force Recommends Screening for Lung Cancer in High-risk Individuals
The U.S. Preventive Services Task Force posted its final evidence report and draft recommendation statement on screening for lung cancer. The Task Force is providing an opportunity for public comment on this draft recommendation statement; comments can be submitted from July 30 to August ...
NCI Working Group Recommends Changes to Screenings, Treatments, and the Definition of Cancer
A growing concern that hundreds of thousands of men and women are undergoing unnecessary and sometimes harmful treatments for premalignant and slow-growing, low-risk cancerous lesions that may never cause harm has led scientists from a working group of the National Cancer Institute to recommend a...
Intratumoral IL-12 Injections Shrink Melanoma and Merkel Cell Tumors
Intratumoral injections of plasmid DNA encoding interleukin-12 (IL-12), facilitated in its delivery by electroporation, results in tumor regression in patients with both metastatic melanoma and Merkel cell carcinoma, according to findings reported at the 2013 World Cutaneous Malignancies Congress...
Molecular Relative of p53 Tumor-suppressor Protein also Helps Cancer Cells Thrive
The protein TAp73 shares extensive common gene sequences with the tumor-suppressor protein p53, and previous studies have suggested that it may function similarly to p53 to prevent tumor formation. However, unlike p53, the most commonly mutated gene in human tumors, TAp73 is rarely mutated and is...
Use of Androgen Deprivation Therapy for Treatment of Prostate Cancer Associated with Increased Risk of Acute Kidney Injury
In a study that included more than 10,000 men with nonmetastatic prostate cancer, use of androgen deprivation therapy was associated with a significantly increased risk of acute kidney injury, with variations observed with certain types of androgen deprivation therapies, according to a study in the ...
Nerves Play Key Role in Triggering Prostate Cancer and Promoting Metastases
Researchers at Albert Einstein College of Medicine of Yeshiva University have found that nerves play a critical role in both the development and spread of prostate tumors. Their findings, using both a mouse model and human prostate tissue, may lead to new ways to predict the aggressiveness of...
Study Confirms Link Between High Blood Levels of Omega-3 Fatty Acids and Increased Risk of Aggressive Prostate Cancer
A second large, prospective study by scientists at Fred Hutchinson Cancer Research Center has confirmed the link between high blood concentrations of omega-3 fatty acids and an increased risk of prostate cancer. Study Details Published online in the Journal of the National Cancer Institute, the...
New Drug Application Submitted for Ibrutinib in the Treatment of Two B-cell Malignancies
Pharmacyclics, Inc, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational oral Bruton's tyrosine kinase inhibitor ibrutinib, for two relapsed/refractory B-cell malignancy indications: mantle cell lymphoma (MCL) and...
Infertility in Men Raises Their Risk for Cancer
A cohort study of 2,238 men who were evaluated for infertility at a clinic in Texas from 1989 to 2009 found that those men who had azoospermia, a condition in which no measurable sperm is present, had a 2.2-fold higher cancer risk compared with those who were nonazoospermic. The study was published ...
Proton Radiation Is Not Associated with Increased Risk of Secondary Cancers When Compared with Photon Radiation
A retrospective cohort study of 558 patients treated with proton radiation from 1973 to 2001 at the Harvard Cyclotron Laboratory in Cambridge, Massachusetts, and data from 558 matched patients treated with photon therapy in the Surveillance, Epidemiology, and End Results (SEER) Program cancer...
Progression of Renal Cell Carcinoma Linked to Shifts in Tumor Metabolism
Investigators in The Cancer Genome Atlas (TCGA) Research Network have uncovered a connection between how tumor cells use energy from metabolic processes and the aggressiveness of the most common form of kidney cancer, clear cell renal cell carcinoma. Their findings demonstrate that normal...
BRAF Mutation Status May Have Effect on Benefit of Aspirin Use for Patients with Colorectal Cancer
In two large studies, the association between aspirin use and risk of colorectal cancer was affected by BRAF mutation status, with regular aspirin use associated with a lower risk of BRAF wild-type colorectal cancer but not with risk of BRAF-mutated cancer. The findings, published today in JAMA,...
New Study Finds AICR Recommendations Cut Breast Cancer Risk
Postmenopausal women who follow at least five Recommendations for Cancer Prevention from the American Institute for Cancer Research (AICR) cut their risk of developing breast cancer by more than half, compared to those who meet none, suggests a new study that adds to previous research showing...
Chemotherapy-induced Neuropathy Has Long-term Effect on Colorectal Cancer Survivors
In a study reported in Journal of Clinical Oncology, Floortje Mols, PhD, of the Center of Research on Psychology in Somatic Diseases, Tilburg University, and colleagues assessed the prevalence and severity of chemotherapy-induced neuropathy and its affect on health-related quality of life in...
High Rate of Durable Remissions with BTK Inhibitor Ibrutinib in Patients with Relapsed Chronic Lymphocytic Leukemia
Durable remissions are uncommon with current treatments for relapsed chronic lymphocytic leukemia (CLL). Bruton’s tyrosine kinase (BTK) is an essential component of B-cell receptor signaling that mediates interactions with the tumor microenvironment and promotes survival and proliferation of...
Researchers Identify and Map Signaling Pathway from EGFR to MCM7 Protein
Researchers have discovered and mapped the signaling network between two previously unconnected proteins, exposing a link that, if broken, could cut off cancer cell growth at its starting point. A team led by scientists at The University of Texas MD Anderson Cancer Center reported the tie between...
Follicular Lymphoma Cells Induce Changes in T-cell Gene Expression and Function, Show Prognostic Significance for Survival
It has been shown that CD4 and CD8 tumor-infiltrating lymphocytes in follicular lymphoma have impaired function and suppressed recruitment of critical signaling proteins to the immunologic synapse, and a number of studies have indicated the prognostic importance of the immune microenvironment in...
Virus Combination Effective Against Temozolomide-resistant Glioblastoma Multiforme
A combination of the myxoma virus and the immune suppressant rapamycin can kill glioblastoma multiforme, the most common and deadliest malignant brain tumor, according to new research published in Neuro-Oncology. Study lead author Peter A. Forsyth, MD, Chair of the Neuro-oncology Program at Moffitt ...
Screening Colonoscopy Associated with Increased Survival Duration and Rates for Patients with Colon Cancer
Patients with colon cancer identified on screening colonoscopy appear to have lower-stage disease on presentation and better outcomes independent of their staging, according to a report published online today in JAMA Surgery. Since their introduction in 2000, National Institutes of Health...
Novel Selective ALK Inhibitor Demonstrates Good Activity in Advanced NSCLC
Crizotinib (Xalkori), a multitargeted receptor tyrosine kinase inhibitor, is the only agent currently available for treating ALK-rearranged non–small cell lung cancer (NSCLC). CH5424802 is a novel selective oral ALK inhibitor with activity in tumor cell lines harboring ALK alterations,...
NCI Will No Longer Accept R01 and P01 Applications for Phase III Clinical Trials of Medical Interventions and Cancer Imaging Modalities
The National Cancer Institute (NCI) has announced that it will no longer accept investigator-initiated R01 and P01 applications that propose phase III clinical trials for cancer-related medical interventions or cancer imaging modalities. The policy change takes effect starting with the due date of...
Abnormalities in New Molecular Pathway May Increase Breast Cancer Risk
A new molecular pathway involving the gene ZNF365 has been identified, and abnormalities in that pathway may predict worse outcomes for patients with breast cancer, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research. “Genomic...
Osteoporosis Drug Stops Growth of Breast Cancer Cells in Tamoxifen-resistant Tumors
A drug approved in Europe to treat osteoporosis has now been shown to stop the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies, according to a study presented at the Endocrine Society’s 95th Annual Meeting in San Francisco. The findings ...
Human Genes May Not Be Patented, Rules the Supreme Court
The U.S. Supreme Court ruled unanimously on Thursday that isolated human genes may not be patented. However, the creation of synthetic forms of DNA, known as complementary DNA (cDNA), is eligible for patent protection. The decision resolves the question brought before the Supreme Court justices in...
ASCO 2013: Lung Cancer Mutations ALK and ROS1 Also Drive Colorectal Cancer
A study from the University of Colorado Cancer Center shows that the ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. Results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset of...
Research Team Identifies Genetic Risk for Cancer in Breast Cells
An Indiana University cancer researcher and his Canadian collaborator have discovered how normal breast precursor cells may be genetically vulnerable to developing into cancer. David Gilley, PhD, Associate Professor of Medical and Molecular Genetics at the IU School of Medicine and a researcher at ...
Radioimmunotherapy/Chemotherapy Combination Could Extend Survival in Some Patients with Advanced Lymphoma
A new patient protocol for aggressive and recurrent lymphoma that combines intensive chemotherapy and radioimmunotherapy showed encouraging overall survival rates in some patients preparing for autologous bone marrow transplant, reported researchers at the 2013 Annual Meeting of the Society of...
National Institutes of Health Issues Projected Impact of Sequestration on Programs
Earlier this month, the National Institutes of Health (NIH) released its updated projections of reductions in programs due to the deficit-budget mechanism known as sequestration, which took effect on March 1, 2013. The sequestration law requires NIH to cut 5%, or $1.55 billion, of its fiscal year...
FDA Clears Multicenter Trial of Treatment for Chemotherapy-related Hair Loss
The FDA has approved initiation of a multicenter trial of the DigniCap System, a scalp-cooling device for chemotherapy-related hair loss. The trial is the second and final phase of study for the DigniCap System. A pilot study previously conducted by researchers at the University of California San...
DNA Sequencing Reveals Mucosal Melanoma's Genetic Fingerprint
Scientists have found a molecular "bullseye" for a rare form of melanoma, opening up opportunities for novel targeted treatment, according to new research published in the Journal of Pathology. Whole genome and whole exome sequencing carried out at Cancer Research UK’s Paterson Institute for ...
PTEN Variant Demonstrates Tumor Suppressor and Regression Activity in Human and Animal Tissue
A novel gene variant found in human and animal tissue may be a promising treatment for cancer, including breast and brain cancer, according to scientists from the Icahn School of Medicine at Mount Sinai. The variant, called PTEN-Long, may contribute to a cell’s healthy function and also...
ASCO 2013: Adapting to Ongoing Shortages of Common Cancer Drugs
A survey of 214 U.S. oncologists and hematologists found that more than 80% encountered cancer drug shortages between March and September of 2012, and many reported that shortages affected the quality of patient care they were able to provide. As physicians were forced to substitute more expensive...
ASCO 2013: 10 Years of Tamoxifen Better Than 5 in Reducing Breast Cancer Recurrence and Death
Ten years of adjuvant treatment with tamoxifen reduces breast cancer recurrence and mortality among women treated for early-stage estrogen receptor (ER)–positive breast cancer, according to results of the British phase III aTTom study. These findings, presented at the 2013 ASCO Annual Meeting ...
ASCO 2013: Sorafenib Stalls Growth of Treatment-resistant Differentiated Thyroid Cancer
A randomized phase III study found that the targeted drug sorafenib (Nexavar) stalls disease progression by 5 months in patients with metastatic differentiated thyroid cancer that has progressed despite standard radioactive iodine therapy. If approved in this setting by the U.S. Food and Drug...
New Research Shows Significant Improvement in Overall Survival Outcomes for Patients Receiving Blood Stem Cell Transplants
Survival rates have increased significantly among patients who received blood stem cell transplants from both related and unrelated donors, according to a study published in the Journal of Clinical Oncology. The study authors attribute the increase to several factors, including advances in HLA...
EGFR Prevents Maturation of Cancer-fighting microRNAs under Hypoxia
Under conditions of oxygen starvation often encountered by tumors, the epidermal growth factor receptor (EGFR) sends signals that thwart the development of tumor-suppressing microRNAs, an international team led by scientists at The University of Texas MD Anderson Cancer Center discovered. The...
Mayo Clinic Genomic Analysis Lends Insight to Prostate Cancer
Mayo Clinic researchers have used next-generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings appear online today in the journal Cancer Research. Gleason Patterns...
Low-dose CT Detects Twice as Many Early-stage Lung Cancers as Chest X-ray, According to Additional NLST Results
Physicians have more information to share with their patients about the benefits and risks of low-dose computed tomography (CT) lung cancer screening following the publication in the New England Journal of Medicine of the results of the first (of three planned) annual screening examinations from...
ASCO 2013: Phase I Trial Suggests Ipilimumab and PD-1 Drug Nivolumab May Be Better Together than Alone for Advanced Melanoma
Results from a phase I study show that combination therapy with ipilimumab (Yervoy) and the investigational antibody drug nivolumab led to lasting tumor shrinkage in approximately half of patients with aggressive, advanced melanoma. The results will be presented at the 2013 ASCO Annual Meeting in...
Study: Popular Diabetes Drug Does Not Improve Survival Rates after Cancer
Despite previous scientific studies suggesting that the diabetes drug metformin has anticancer properties, a new, first-of-its-kind study from Women’s College Hospital in Toronto has found the drug may not actually improve survival rates after breast cancer in certain patients. The study,...
Blocking a Single Gene Renders Tumors Less Aggressive, Johns Hopkins Researchers Find
Researchers at Johns Hopkins have identified a gene that, when repressed in tumor cells, puts a halt to cell growth and a range of processes needed for tumors to enlarge and spread to distant sites. The researchers hope that this so-called “master regulator” gene may be the key to...
FDA Warns about Potential Medication Errors Resulting from Confusion Regarding Nonproprietary Name for Kadcyla (ado-trastuzumab emtansine)
The U.S. Food and Drug Administration (FDA) is alerting health-care professionals that the use of the incorrect nonproprietary name for the breast cancer drug Kadcyla (ado-trastuzumab emtansine, also known as T-DM1 during preapproval clinical trials) in some medication-related electronic systems...
Researchers Identify New Pathway, Enhancing Tamoxifen to Tame Aggressive Breast Cancer
Tamoxifen is a time-honored breast cancer drug used to treat millions of women with early-stage and less-aggressive disease, and now a University of Rochester Medical Center (URMC) team has shown how to exploit tamoxifen’s secondary activities so that it might work on more aggressive breast...
